Top

Osteoporosis International

Published in:

19-01-2024 | Selective Estrogen Receptor Modulator | Original Article

Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment: based on the National Health Claims Database 2017–2019

Authors: Seong-Eun Byun, Hasung Kim, Seung yun Lee, Sang-Min Kim

Published in: Osteoporosis International | Issue 5/2024

Abstract

Summary

With the analysis of nationwide health claim data, treatment with the composite agent of SERMs and vitamin D reduces the risk of osteoporotic fracture and hip fracture better compared to SERMs treatment in women with osteoporosis aged ≥ 50 years.

Purpose

This study compared the potential of the composite agent of selective estrogen receptor modulators (SERMs) and vitamin D (SERM + VitD) with that of SERMs-only for fracture prevention and mortality reduction in women aged ≥ 50 years.

Methods

The incidence of osteoporotic fracture (fractures of the vertebrae, hip, wrist, or humerus) and all-cause death after treatment with SERM + VitD and SERMs were characterized using the Korean National Health Insurance Service database 2017–2019. The participants were divided into two groups (SERM + VitD vs SERMs). After exclusion and propensity score matching, 2,885 patients from each group were included in the analysis. Fracture incidence was compared between groups. Kaplan–Meier curves were used to compare mortality. Cox proportional hazards regression analysis was used to compare the risks of fracture occurrence and mortality between the groups.

Results

The incidence rate (138.6/10,000 vs. 192.4/10,000 person-years), and risk of osteoporotic fractures (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.61–0.97; p = 0.024) were lower in the SERM + VitD group than in the SERMs group. Analysis for specific fractures showed a lower hazard of hip fracture in the SERM + VitD group (HR, 0.25; 95% CI, 0.09–0.71; p = 0.009). No difference was observed between the groups regarding mortality.

Conclusion

The risk of osteoporotic fractures, especially hip fractures, was lower in the SERM + VitD group than in the SERMs group. Therefore, the composite agent of SERMs and vitamin D can be considered as a viable option for postmenopausal women with a relatively low fracture risk.

Available only for authorised users

Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10:592–602CrossRefPubMed

Kim KW, Kim OS (2020) Super aging in South Korea unstoppable but mitigatable: a sub-national scale population projection for best policy planning. Spat Demogr 8:155–173. https://doi.org/10.1007/s40980-020-00061-8CrossRefPubMedPubMedCentral

Riggs BL, Hartmann LC (2003) drug therapy selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348:618–629CrossRefPubMed

Lee N, Choi YJ, Chung Y-S (2020) The secular trends in the use of medications for osteoporosis in South Korea using Intercontinental Medical Statistics Health Sales Audit 2006–2018. Osteoporos Sarcopenia 6:185–190. https://doi.org/10.1016/j.afos.2020.11.007CrossRefPubMedPubMedCentral

Ceglia L (2009) Vitamin D and Its role in skeletal muscle. Curr Opin Clin Nutr Metab Care 12:628–633. https://doi.org/10.1097/MCOCrossRefPubMedPubMedCentral

Feng Y, Cheng G, Wang H, Chen B (2017) The associations between serum 25-hydroxyvitamin D level and the risk of total fracture and hip fracture. Osteoporos Int 28:1641–1652. https://doi.org/10.1007/s00198-017-3955-xCrossRefPubMed

Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int 23:2479–2487. https://doi.org/10.1007/s00198-011-1868-7CrossRefPubMedPubMedCentral

Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:1–46CrossRefPubMed

Yoo JI, Ha YC, Park KS et al (2019) Incidence and mortality of osteoporotic refractures in Korea according to nationwide claims data. Yonsei Med J 60:969–975. https://doi.org/10.3349/ymj.2019.60.10.969

10.

Balasubramanian A, Tosi L, Lane J et al (2014) Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 96:e52

11.

Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739. https://doi.org/10.1359/jbmr.2000.15.4.721CrossRefPubMed

12.

Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139CrossRefPubMed

13.

Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137CrossRefPubMed

14.

Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637–645

15.

Khalid S, Calderon-Larrañaga S, Hawley S et al (2018) Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the uk clinical practice research database and the catalan sidiap database. Clin Epidemiol 10:1417–1431. https://doi.org/10.2147/CLEP.S164112CrossRefPubMedPubMedCentral

16.

Bischoff-Ferrari H, Dietrich T, Orav E, Dawson-Hughes B (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116:634–639CrossRefPubMed

17.

Bischoff-Ferrari HA, Willett WC, Wong JB et al (2005) Fracture prevention with vitamin D supplementation. JAMA 293:2257–2264CrossRefPubMed

18.

LeBoff MS, Chou SH, Ratliff KA et al (2022) Supplemental vitamin D and incident fractures in midlife and older adults. N Engl J Med 387:299–309. https://doi.org/10.1056/nejmoa2202106CrossRefPubMedPubMedCentral

19.

Anagnostis P, Bosdou JK, Kenanidis E et al (2020) Vitamin D supplementation and fracture risk: evidence for a U-shaped effect. Maturitas 141:63–70. https://doi.org/10.1016/j.maturitas.2020.06.016CrossRefPubMed

20.

Park JH, Hong IY, Chung JW, Choi HS (2018) Vitamin D status in South Korean population: seven-year trend from the KNHANES. Medicine (Baltimore) 97:e11032. https://doi.org/10.1097/MD.0000000000011032CrossRefPubMed

21.

Yoo KO, Kim MJ, Ly SY (2019) Association between vitamin d intake and bone mineral density in Koreans aged ≥ 50 years: analysis of the 2009 Korea National Health and Nutrition Examination Survey using a newly established vitamin D database. Nutr Res Pract 13:115–125. https://doi.org/10.4162/nrp.2019.13.2.115

22.

Gorai I, Hattori S, Tanaka Y, Iwaoki Y (2012) Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Metab 30:349–358CrossRefPubMed

23.

Liu HJ, Kim SA, Shim DJ et al (2019) Influence of supplementary Vitamin D on bone mineral density when used in combination with selective estrogen receptor modulators. J Menopausal Med 25:94. https://doi.org/10.6118/jmm.19193CrossRefPubMedPubMedCentral

24.

Zhang Y, Fang F, Tang J et al (2019) Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ 366:l4673CrossRefPubMedPubMedCentral

25.

Keum N, Lee DH, Greenwood DC et al (2019) Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol 30:733–743CrossRefPubMedPubMedCentral

26.

Neale RE, Baxter C, Romero BD et al (2022) The D-health trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol 10:120–128. https://doi.org/10.1016/S2213-8587(21)00345-4CrossRefPubMed

Title: Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment: based on the National Health Claims Database 2017–2019
Authors: Seong-Eun Byun
Hasung Kim
Seung yun Lee
Sang-Min Kim
Publication date: 19-01-2024
Publisher: Springer London
Keywords: Selective Estrogen Receptor Modulator
Osteoporosis
Osteoporosis
Published in: Osteoporosis International / Issue 5/2024
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-024-07022-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment: based on the National Health Claims Database 2017–2019

Abstract

Summary

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2024

Prunes preserve cortical density and estimated strength of the tibia in a 12-month randomized controlled trial in postmenopausal women: The Prune Study

Comment on: Bone density and fracture risk factors in ankylosing spondylitis: a meta-analysis

Physical performance and sarcopenia assessment in patients with a recent fracture visiting the Fracture Liaison Service

Predictors of atypical femoral fractures: experience of a Portuguese Fracture Liaison Service

An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case–control study

Bone mineral density, turnover, and microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography in patients with Sheehan’s syndrome